131 related articles for article (PubMed ID: 38521551)
1. Corrigendum to "Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients" [Journal of Global Antimicrobial Resistance 36 (2024) 252-259].
You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F
J Glob Antimicrob Resist; 2024 Mar; 36():494. PubMed ID: 38521551
[No Abstract] [Full Text] [Related]
2. Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Rao Z; Dang ZL; Li B; Zhu L; Qin HY; Wu XA; Wei YH
Ther Drug Monit; 2020 Aug; 42(4):578-587. PubMed ID: 32049891
[TBL] [Abstract][Full Text] [Related]
3. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
[TBL] [Abstract][Full Text] [Related]
4. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
5. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
[TBL] [Abstract][Full Text] [Related]
7. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
[TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P
Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
11. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
14. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
16. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
17. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
18. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
19. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
[No Abstract] [Full Text] [Related]
20. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
